iForum 2016 : Disease Modeling & Reg Med (11 Oct, Paris)

Organized by Cellular Dynamics International.

Venue : Institut du Cerveau et de la Moelle Epiniere, Paris
Date : Oct 11th, 2016

Introducing the iForum™ 2016 Meeting: Europe, a full day event for users of iPSC-derived cells. The iForum 2016 Meeting provides a unique opportunity to connect with thought leaders from academia, government, biotech and pharma to discover new applications and uses for differentiated iPS cells. The meeting will include innovative scientific talks and poster sessions, as well as an evening event to relax with colleagues. Space is limited – so register today.


  • Marc Peschanski, PhD, Scientific Director, I-Stem Institute
    Harnessing Human Pluripotent Stem Cells for Pharmacology


  • Benjamin Morlon, PhD, Manager of Business Development, ICM – Brain & Spine Institute
    An Introduction to ICM, The Brain & Spine Institute
  • Claus Rieker, PhD, Brain Health Specialist, Brain Health Platform, Nestlé Institute of Health Sciences
    Alzheimer’s Disease and APOE4
  • Georg Rast, PhD, Principal Scientist, Boehringer Ingelheim Pharma
    Relationship of Field Potential, Duration and Spontaneous Rate in hiPSC-derived Cardiomyocytes
  • Dries Braeken, PhD, Research & Development Team Leader. Life Science Technologies Department, IMEC
    Advanced Electrophysiology Silicon Technologies for Cell-based Applications
  • Camille Nicoleau, PhD, Principal Scientist, In Vitro Toxin Group Global Drug Discovery, Ipsen Innovation
    The Potential of Using Human Induced Pluripotent Stem Cells for the Study of Botulinum Neurotoxins
  • Jean Philippe Stephan, PhD, Department Head, HTS Department Biotechnology, Servier
    New Generation Phenotypic Screens: The Missing Link!
  • Ángel Raya, MD, PhD, Professor, Center of Regenerative Medicine CMR Barcelona
    Opportunities of iPS Cell Technology for Modeling Neurodegenerative Diseases
  • Andreas Mühlemann, PhD, Senior Lab Head, CNS Biology, Actelion Pharmaceuticals Ltd
    Characterization and Implementation of iPSC-derived Neurons in Phenotypic Drug Discovery
  • Amy Pointon, PhD, Associate Principal Scientist, Drug Safety and Metabolism, AstraZeneca
    Use of Stem Cell-derived Cardiomyocyte 2D and 3D Models for the Detection of Cardiotoxicity
  • Remco Westerink, PhD, Head, Neurotoxicology Research Group at the Institute for Risk Assessment Sciences (IRAS), Utrecht University
    Using Human iPSC-derived Neurons for Functional Neurotoxicity Testing in Vitro